Pure Global
NCT01466231

Everolimus in Refractory Testicular Germ Cell Cancer

Phase II Study of Everolimus in Refractory Testicular Germ Cell Cancer.
National Cancer Institute, Slovakia·Phase 2·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Germ Cell Tumor
Drug/Device/Intervention
Everolimus
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
National Cancer Institute, Slovakia
Location
Bratislava, Slovakia
Timeline & enrollment
Phase
Phase 2
Start date
Nov 01, 2011
End date
Jun 01, 2015
Enrollment
15 participants
Primary outcome

Response rate

Summary

Everolimus in refractory testicular germ cell cancer. Everolimus 10 mg /day/ is administered
 to the patient until progression, unacceptable toxicity, complete response or inability of
 the subject to comply with study requirements. Feasibility of surgical resection will be
 assessed after every 2 cycles of the treatment in patients with partial response.

ICD-10 classifications
Malignant neoplasmsMalignant neoplasm: JejunumMalignant neoplasm: PrepuceMalignant neoplasm: Female genital organ, unspecifiedMalignant neoplasm: Vulva, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT01466231
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT01466231 through Pure Global AI's free database. This Phase 2 trial is sponsored by National Cancer Institute, Slovakia and is currently Completed. The study focuses on Germ Cell Tumor. Target enrollment is 15 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.